Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
true falseYou successfully added item(s) to your cart
For laboratory use only. This product is intended for animal research only and not for use in humans.
MMPSense 750 FAST is an activatable fluorescent imaging agent comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.
MMPSense 750 FAST is a matrix metalloproteinase (MMP) activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by disease related MMP’s. Activation can occur by a broad range of MMP’s including MMP 2, 3, 7, 9, 12, and 13.
MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis, rheumatoid arthritis, pulmonary diseases and areas of cardiovascular disease. MMPSense 750 FAST may be used to monitor the progression of these diseases or to evaluate the potential therapeutic efficacy of drugs targeting the underlying mechanisms involved in these diseases.
| Fluorescent Agent Type | Activatable |
|---|---|
| Optical Imaging Classification | Fluorescence Imaging |
| Product Brand Name | MMPSense |
| Quantity in a Package Amount | 1.0 Units |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer |
| Unit Size | 1 Vial (10 doses) |
| Wave Length | 750 nm |
Integrins are a family of transmembrane glycoproteins which play a crucial role in the pathogenesis of various diseases, including cancer, and as such represent viable biomarkers for the progression of these diseases. We have developed IntegriSense 680, an integrin-targeted molecular imaging agent that allows the non-invasive imaging of disease status and progression.
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.
MMPSense 750 FAST is the first in a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.
MMPSense 750 FAST activatable fluorescent imaging agent protocol
